M. Brammer

发表

Estimating recurrences prevented from using trastuzumab in HER‐2/neu–positive adjuvant breast cancer in the United States

K. Knopf, Q. Doan, M. Danese, 2010, Cancer.

Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER

H. Rugo, Lisa I. Wang, I. C. Tudor, 2011, Clinical Cancer Research.

MyPathway: An open-label phase IIa study of trastuzumab/pertuzumab, erlotinib, vemurafenib, and vismodegib in patients who have advanced solid tumors with mutations or gene expression abnormalities targeted by these agents.

E. Perez, J. Hainsworth, C. Swanton, 2015 .

Identification of proteases employed by dendritic cells in the processing of protein purified derivative (PPD)

M. Mohamadzadeh, R. Luftig, K. Sestak, 2004, Journal of immune based therapies and vaccines.

Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens

S. Ramsey, S. Sullivan, R. Hansen, 2014, SpringerPlus.

Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors.

E. Perez, J. Hainsworth, R. Bose, 2016 .

Effect of Central Nervous System Metastases on Treatment Discontinuation and Survival in Older Women Receiving Trastuzumab for Metastatic Breast Cancer

K. Lindquist, M. Danese, R. Griffiths, 2012, Journal of cancer epidemiology.

Abstract 5287: Heterogeneity of mutation calling and annotation: a survey of cancer next-generation sequencing initiatives by the Global Alliance for Genomics and Health (GA4GH):

Subha Madhavan, Emmanuel Dias-Neto, Thomas J. Hudson, 2016 .

Survival of patients with HER2+ metastatic breast cancer and use of trastuzumab following progression: analysis of RegistHER.

M. Birkner, H. Rugo, S. Paik, 2009 .

Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population

S. Gomez, A. Kurian, Marjorie C. Green, 2016, Cancer Causes & Control.

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer

Peter A Kaufman, K. Bloom, H. Rugo, 2014, Cancer.

Assessing the potential cost‐effectiveness of retesting IHC0, IHC1+, or FISH‐negative early stage breast cancer patients for HER2 status

Bruce Wang, E. Perez, L. Garrison, 2013, Cancer.

Adult T‐cell leukemia‐lymphoma unusual features of two patients from a low‐incidence area

S. Rangan, M. Brammer, J. J. Temple, 1986, Cancer.

Bevacizumab confers additional advantage to the combination of trastuzumab plus pertuzumab in trastuzumab-refractory breast cancer model

B. Leyland-Jones, P. De, N. Dey, 2013, Cancer Chemotherapy and Pharmacology.

Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population

S. Gomez, A. Kurian, Marjorie C. Green, 2016, Cancer Causes & Control.

Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States.

M. Danese, A. Masaquel, D. Lalla, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Symptom Burden and Quality of Life among Women with HER2+ Metastatic Breast Cancer

D. Tripathy, J. Menzin, K. Lang, 2015, The breast journal.

The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer.

L. Garrison, A. Masaquel, J. Babigumira, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Health Care Utilization and Costs by Site of Service for Nonmetastatic Breast Cancer Patients Treated with Trastuzumab

L. Becker, A. Teitelbaum, A. Parthan, 2014, Journal of managed care & specialty pharmacy.

Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials.

H. Rugo, Fan Zhang, D. Lalla, 2010, Clinical breast cancer.

Pooled Analysis of Cardiac Safety in Patients Treated with Pertuzumab.

T. Suter, D. Lenihan, G. Ross, 2009 .

Costs associated with chemotherapy-related complications in the treatment of metastatic breast cancer in a real-world setting.

S. Hurvitz, E. Wu, A. Yu, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acceptability of the NCI patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in women with metastatic breast cancer (MBC).

L. Minasian, E. Basch, B. Reeve, 2012 .

Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis

E. Wu, A. Masaquel, D. Lalla, 2014, SpringerPlus.

Infused Therapy and Survival in Older Patients Diagnosed with Metastatic Breast Cancer who Received Trastuzumab

M. Danese, R. Griffiths, R. Herbert, 2011, Cancer investigation.

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.

Zheng-Yi Zhou, S. Hurvitz, E. Wu, 2014, The Oncologist.

Targeted therapy for advanced solid tumors based on molecular profiles: Early results from MyPathway, an open-label, phase IIa umbrella basket study.

J. Hainsworth, R. Bose, C. Swanton, 2016 .

P1-08-22: Treatment Patterns and Clinical Outcomes in Elderly Patients with HER2−Positive Metastatic Breast Cancer from the registHER Observational Study.

H. Rugo, D. Tripathy, D. Yardley, 2011 .

Journal of Immune Based Therapies and Vaccines Identification of Proteases Employed by Dendritic Cells in the Processing of Protein Purified Derivative (ppd)

M. Mohamadzadeh, R. Luftig, K. Sestak, 2022 .